Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae
Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae
复制标题
DOI：
10.1111/j.1348-0421.2008.00050.x
复制
发表时间：
2008-08-01
影响因子：
2.6
通讯作者：
Alvarez, Susana
中科院分区：
文献类型：
--
作者：
Medina, Marcela;Villena, Julio;Alvarez, Susana
乳酸乳球菌NZ 9000是一种非致病性非侵入性细菌，广泛用于在粘膜水平递送抗原和细胞因子。然而，没有关于该菌株本身免疫调节能力的报道。本研究的目的是研究鼻腔给药L。乳链球菌NZ 9000在肺炎球菌感染模型中的作用。小鼠用L.乳酸菌（2、5或7天，每只小鼠10（8）个细胞/天），然后用肺炎链球菌攻击。评价局部和全身免疫应答。结果表明，L.乳酸菌素5天（LLN 5d）可提高S.从肺中分离肺炎球菌，并阻止肺炎球菌传播到血液中。这种效应与局部和全身区室中的先天性和特异性免疫应答的上调相一致。通过NBT和过氧化物酶试验测定，LLN 5d增加肺、血液和骨髓中的吞噬细胞活化。LLN 5 d组支气管肺泡灌洗液（BAL）中抗肺炎球菌免疫球蛋白（IG）A以及BAL和血清中IgG升高。肺组织病理学检查显示，LLN 5d治疗可减轻肺组织损伤。检查和BAL中的白蛋白浓度和乳酸脱氢酶活性。L.乳酸杆菌在我们的感染模型中的应用将是其作为肺炎球菌蛋白的递送载体和用重组乳酸杆菌进行鼻免疫的重要优势。乳酸作为一种有效的疫苗接种途径出现，用于对抗肺炎球菌感染的全身和粘膜免疫。
Lactococcus lactis NZ9000 is a non-pathogenic non-invasive bacterium extensively used for the delivery of antigens and cytokines at the mucosal level. However, there are no reports concerning the per se immunomodulatory capacity of this strain. The aim of the present study was to investigate the intrinsic immunostimulating properties of the nasal administration of L. lactis NZ9000 in a pneumococcal infection model. Mice were preventively treated with L. lactis (2, 5 or 7 days with 10(8) cells/day per mouse) and then challenged with Streptocroccus pneumoniae. The local and the systemic immune responses were evaluated. Our results showed that nasal administration of L. lactis for 5 days (LLN5d) increased the clearance rate of S. pneumoniae from lung and prevented the dissemination of pneumococci into blood. This effect coincided with an upregulation of the innate and specific immune responses in both local and systemic compartments. LLN5d increased phagocyte activation in lung, blood and bone marrow, determined by NBT and peroxidase tests. Anti-pneumococcal immunoglobulin (Ig)A in bronchoalveolar lavages (BAL) and IgG in BAL and serum were increased in the LLN5d group. Lung tissue injury was reduced by LLN5d treatment as revealed by histopathological. examination and albumin concentration and lactate dehydrogenase activity in BAL. The adjuvant effect of L. lactis in our infection model would be an important advantage for its use as a delivery vehicle of pneumococcal proteins and nasal immunization with recombinant L. lactis emerges as an effective route of vaccination for both systemic and mucosal immunity against pneumococcal infection.